Methylation of secreted frizzle-related protein (SFRP) genes activates Wnt/-catenin signaling and promotes tumor development. This study investigated whether SFRP5 gene methylation causes multidrug resistance (MDR) in leukemia through the Wnt/-catenin signaling, leading to the upregulation of the mdr1 gene and its product, P-glycoprotein (P-gp). Methylation-specific PCR identified SFRP5 gene methylation in cultured bone mononuclear cells from 7/12 patients with acute leukemia and in four human leukemia cell lines (HL-60, Raji, U937 and KG1a). Western blotting revealed absent SFRP5 protein expression in cells from 5/7 patients with SFRP5 gene methylation and in all cell lines. Treatment with a demethylation agent (DAC) rescued SFRP5 expression. mdr1 mRNA and P-gp protein were detected in cells from 3/5 patients with absent SFRP5, and in the KG1a cell line; these cells also had the highest levels of activated -catenin. In cells from these three patients, DAC rescued SFRP5 expression and downregulated mdr1 and P-gp. SFRP5 protein expression was rescued in transgenic KG1a/SFRP5 cells, compared with KG1a/eGFP or untransfected KG1a cells. mdr1 and P-gp in KG1a/SFRP5 cells were downregulated. Doxorubicin IC 50 values were significantly lower in KG1a/SFRP5 (0.573±0.131 mM) than in KG1a (0.963±0.115) or KG1a/eGFP (0.917±0.138) cells (Po0.05). We conclude that SFRP5 gene methylation in leukemia cells activates Wnt/-catenin signaling to upregulate mdr1/P-gp expression and cause MDR. Recovery of SFRP5 expression reversed MDR in the KG1a leukemia cell line. Our results suggest that modulating SFRP5 methylation could decrease MDR in leukemia patients.
INTRODUCTION
Secreted frizzle-related proteins (SFRPs) are a large family of proteins sharing structural similarities with the frizzle (Fz) receptor. 1 Abnormal activation of SFRPs is associated with tumor occurrence and progression, and the methylation of SFRP genes is involved in this process. 2, 3 SFRP5 gene methylation and associated reductions in SFRP5 protein expression were identified in human renal cancer cell lines 4 and in cervical adenocarcinoma, whereas SFRP5 rescue inhibits cancer growth. 5 Multidrug resistance (MDR) in leukemia cells is the main cause of treatment failure. 6 MDR occurs when exposure to an anti-cancer drug results in the development of resistance to other chemotherapeutic agents. 7 A major cause of MDR is P-gp overexpression, encoded by the mdr1 gene. 8 P-gp is a membrane transport protein extruding cytotoxic drugs from the cell, decreasing intracellular drug levels and hence their efficacy. 8 The Wnt pathway is involved in the regulation of cell proliferation, differentiation and apoptosis in adults, as well as in leukemia development. 9, 10 Activation of the Wnt/-catenin pathway promotes mdr1 gene transcription and P-gp expression. 11 Methylation of SFRPs was reported in leukemia, 12 acute lymphocytic leukemia 13 and chronic lymphatic leukemia. 14 In acute myeloid leukemia (AML), SFRP5 gene methylation is associated with decreased SFRP5 expression and with an increased recurrence risk. 15 SFRP5 inhibits Wnt signaling, 16 and SFRP5 gene methylation is associated with cisplatin-resistance in ovarian cancer. 17 However, the roles of SFRP5 gene methylation and mdr1 in leukemia are mostly unknown, and the present study is the first to directly shed some light on these points. Therefore, the aim of this study was to investigate whether SFRP5 gene methylation and associated changes in SFRP5 protein expression have a role in the development of MDR in leukemia through activation of the Wnt/-catenin pathway and enhanced P-gp expression, using cultured cells from patients with acute leukemia and human leukemia cell lines. In addition, transgenic KG1a cells were constructed to determine whether recovery of SFRP5 in these cells would influence mdr1 mRNA expression and P-gp protein expression, as well as resistance to a cytotoxic agent. Results from the present study might reveal pathways that could be targeted to decrease MDR in leukemia patients.
MATERIALS AND METHODS

Subjects' bone marrow mononuclear cells
Between June and December 2011, bone marrow mononuclear cells were collected from 12 patients (L1-L12) diagnosed with acute leukemia at the Shengjing Hospital of China Medical University (Shenyang, China). The diagnoses, made according to the World Health Organization (WHO) criteria, were as follows: L1, acute lymphocytic leukemia; L2, chronic granulocytic leukemia; L3, AML-M4; L4, AML-M2; L5, chronic granulocytic leukemia; L6, AML-M4; L7, chronic granulocytic leukemia; L8, AML-M2; L9, acute lymphocytic leukemia; L10, AML-M4Eo; L11, AML-M5 and L12, AML-M6. During the same period, bone marrow cells were obtained from six control patients who presented with fever, low blood platelets and high leukocyte count, but in whom hematological disease was excluded by bone marrow puncture. All experiments were approved by our Ethics Committee and written informed consent was obtained from each participant.
Anti-coagulated bone marrow was diluted with phosphate-buffered saline (PBS) and separated using a Ficoll lymphocyte separation medium (2500 r.p.m., 20 min at room temperature). The white narrow band containing lymphocytes and monocytes was collected and re-suspended in five volumes of PBS. The mixture was centrifuged (1500 r.p.m., 5 min) and pellets were re-suspended in 4 ml of PBS. Following centrifugation (1000 r.p.m., 5 min), pellets were stored at À 80 1C in serum containing 10% dimethyl sulfoxide and Trizol.
Human leukemia cell lines
The HL-60 cell line was kindly provided by Ying Yang, Hematology Department, Shengjing Hospital of China Medical University (Shenyang, China). The KG1a cell line was obtained from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China). The Raji and U937 cell lines were kindly provided by Professor Lijun Jia, Fudan University (Shanghai, China).
Cell culture
The four cell lines and the mononuclear cells obtained from subjects were cultured in RPMI-1640 medium (Hyclone, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (Solarbio Science & Technology, Beijing, China), at 37 1C in a humidified atmosphere containing 5% of CO 2 .
Construction of KG1a/SFRP5 and KG1A/eGFP cells Bacterial transformation. Single colonies were selected from a DH5a plate, inoculated into 5 ml of 2YT medium and incubated overnight under agitation (200 r.p.m.). The bacterial suspension was then added to 100 ml of 2YT medium and incubated at 37 1C under agitation (200 r.p.m.) for 2-3 h. Cells were harvested, cooled on ice and centrifuged at 4000 r.p.m. for 10 min at 4 1C. The supernatant was discarded and pellets were resuspended in one-tenth the volume of pre-cooled TBS. Competent cells were either used directly for transformation or stored at À 80 1C.
The transformation reaction mixture (100 ml) contained 1 ml of plasmid, 10 ml of buffer, 39 ml of sterile de-ionized water and 50 ml of DH5a competent cells. After incubation on ice for 10 min, 100 ml of 2YT medium was added and incubated at 37 1C under gentle agitation for 90 min. DH5a competent cells (100 ml) were then spread onto 2YT plates (with 100 mg ml À 1 of ampicillin). After air-drying, the plates were incubated at 37 1C for 16 h, along with negative controls.
For the identification of positive clones, the colonies were transferred into 3 ml of medium and harvested for DNA sequencing. Sequences were compared with the target gene sequence using DNASIS software. (Hitachi Software Enginering Company, Tokyo, Japan) Plasmid extraction. Plasmid was extracted and purified using the Qiagen plasmid mini purification kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's instructions, using colonies that were selected and inoculated into 5 ml of 2YT medium (containing 100 mg ml À 1 of ampicillin) and incubated overnight at 37 1C under vigorous agitation.
Transient transfection. Cells were transiently transfected using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Cell suspension was transferred to six-well plates (500 ml per well), and after incubation for 6 h, the medium was replaced with liquid RPMI-1640 medium containing 20% of serum. Cells were incubated for 72 h.
Identification of KG1a/eGFP cells. Fluorescence microscopy (using a drop of cell suspension on a slide covered with a coverslip) and flow cytometry were used to identify eGFP green fluorescence and assess cell transfection efficiency. For cytometry, suspended cells were centrifuged (2000 r.p.m., 5 min), pellets were washed twice with PBS, re-centrifuged (2000 r.p.m., 5 min) and pellets were re-suspended in 400 ml of PBS buffer (B1 Â 10 6 cells ml À 1 ). Harvested cells were analyzed using a flow cytometer (excitation wavelength 488 nm, emission wavelength 510 nm).
Genomic DNA extraction Genomic DNA was extracted using an AxyPrep genomic DNA mini-preparation kit (Invitrogen) according to the manufacturer's instructions, using cells purified by centrifugation in a 2-ml tube at 2000 g for 5 min. DNA was eluted and the DNA concentration was measured by UV spectrometry.
Treatment of genomic DNA with sodium bisulfite Genomic DNA was treated with the MethylCode bisulfite conversion kit (Invitrogen) according to the manufacturer's instructions.
RNA extraction
Total RNA was extracted from cells using Trizol reagent.
2 OD was measured at 260 nm (OD 260 ) and 280 nm (OD 280 ) to estimate the concentration and purity of the RNA. RNA was stored at À 80 1C or reversely transcribed to cDNA.
cDNA synthesis cDNA synthesis reaction mixture (40 ml) contained 8 ml of 5 Â RT buffer, 4 ml of 0.1 M DTT, 1 ml of 10 mM dNTPs, 0.5 ml of 40 U ml À 1 Rnasin, 1 ml of random primers (100 ng ml À 1 ), 2 ml of RNA, 1 ml of M-MLV reverse transcriptase (200 U ml À 1 ) and 39 ml of DEPC water. The mixture was incubated at 37 1C for 1 h and then at 72 1C for 10 min. cDNA products were stored at À 20 1C.
PCR detection of SFRP5 gene methylation
For methylation-specific PCR (MSP), 20 ng of modified DNA, 0.4 ml of methylated upstream primer (10 mM), 0.4 ml of methylated downstream primer (10 mM) (Table 1), 10 ml of 2 Â reaction buffer, 0.2 ml of dNTP mix, 0.16 ml of ZymoTag DNA polymerase (5 U ml
) and 20 ml of sterile distilled water were mixed. For non-MSP PCR, the same procedure was used, but with non-methylated upstream primers. PCR products were analyzed using 2% agarose gel electrophoresis.
RT-PCR assay of mdr1 RNA expression RT-PCR reaction mixture (25 ml) contained 2.5 ml of 10Â buffer, 0.5 ml 10 mM of dNTPs, 1 ml of cDNA, 0.5 ml of forward primer (10 mM), 0.5 ml of Real-time PCR assay of changes in mdr1 RNA expression Real-time PCR was performed on an ABI 7500 Real-Time PCR (Applied Biosystems, Foster City, CA, USA). Reaction mixture (20 ml) contained 10.0 ml of 2 Â SYBR Premix Ex Taq, 0.4 ml of upstream primer (10 mM), 0.4 ml of forward primer (10 mM), 0.4 ml of reverse primer (10 mM) (Table 1) , 0.4 ml of 50X ROX Reference Dye II, 2.0 ml of cDNA and 6.8 ml of sterile doubledistilled H 2 O. Each run was performed in three parallel wells. After reaction, the threshold value was set and the cycle threshold (Ct) value determined by computer.
Western blotting
were harvested by centrifugation (1000 r.p.m., 5-10 min, 4 1C) and washed twice with chilled PBS. Cells were lysed with 1 ml of RIPA lysis buffer (10-30 min on ice, with agitation) and the mixture was centrifuged (12 000 r.p.m., 30 min, 4 1C). Supernatant was rapidly transferred into a pre-chilled centrifuge tube. Protein concentration was measured using a bicinchoninic acid assay. SDS-PAGE (50 mg protein per lane; 10% or 12% gel) was carried out at 8 V cm À 1 (B65 V) for 30 min; voltage was then increased to 15 V cm À 1 (B110 V). Proteins were transferred onto a nitrocellulose (NC) membrane. After washing with PBS, the membrane was blocked with 5% skimmed milk (4 1C, overnight). Subsequently, the membrane was incubated overnight at 4 1C on a rotary shaker with rabbit primary antibodies (1:1000, used at 0.1 ml cm À 2 ) against human SFRP5, non-phosphorylated (NP)--catenin or P-gp. Primary antibodies were removed, the membrane was washed three times with PBST (10 min each) and then incubated for 2 h at room temperature with mouse anti-rabbit secondary antibodies. After washing three times with PBST, an ECL reaction was performed (Beyotime Institute of Biotechnology, Haimen, China), according to the manufacturer's instructions. The protein band was developed and its OD measured using an imaging system.
Detection of cell-surface P-gp using fluorescence microscopy ) were harvested, washed twice with cold PBS buffer and centrifuged (2000 r.p.m., 5 min). Pellets were re-suspended in serum-free liquid RPMI-1640 medium containing 0.3 mM of rhodamine; in additional experiments, 10 mM of verapamil was used as a positive control. Samples were incubated at 37 1C with agitation for 2 h and then centrifuged at 1200 r.p.m. for 10 min. After discarding the supernatant, pellets were washed with PBS and resuspended in 500 ml of PBS. Flow cytometry was used to determine the intracellular fluorescence intensity.
Drug resistance assessment using the MTT method KG1a, KG1a/eGFP or KG1a/SFRP cells were harvested (1 Â 10 5 cells per ml). Cells were inoculated into 96-well plates (100 ml per well). After 8 h of incubation, light microscopy showed that cells exhibited good growth. Doxorubicin was added to a final concentration of 0, 0.1, 0.25, 0.5, 1, 5, 10, 20 or 50 mM. Blank controls were prepared using complete RPMI medium and negative controls were prepared by excluding doxorubicin. Cells were incubated at 37 1C, under 5% CO 2 , for 72 h, with 20 ml of MTT added to each well 4 h before the end of the incubation period. The supernatant was then removed from each well and 150 ml of dimethyl sulfoxide was added, with agitation for 10 min. OD of each cell suspension was measured at 570 nm and the IC 50 value calculated. Each measurement was made in triplicate.
Statistical analysis
Data are presented as mean ± standard deviation. Comparisons among multi-groups were analyzed using ANOVA and between two-groups using t-tests. SPSS 13.0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Po0.05 was considered as statistical significance.
RESULTS
SFRP5 gene methylation
Methylation of the SFRP5 gene was observed in cells from 7/12 patients with leukemia (L2, L4, L5, L6, L7, L8 and L11), but in none of the control subjects (Figure 1a ). SFRP5 gene methylation was also found in all four leukemia cell lines (HL-60, Raji, U937 and KG1a) (Figure 1b ). These data strongly suggest an association between SFRP5 gene methylation and acute leukemia.
SFRP5 methylation decreases SFRP5 protein expression
Western blotting was used to determine SFRP5 protein expression. SFRP5 expression was detected in cells from 7/12 patients with acute leukemia, but was absent in cells from five patients (L2, L4, L7, L8 and L11), all of whom displayed SFRP5 gene methylation (with complete absence of unmethylated gene) (Figure 2a) . Interestingly, patients L5 and L6 displayed both methylated and unmethylated SFRP5 genes (Figure 1a) , and appeared to have reduced SFRP5 protein expression (Figure 2a ), although this was not quantified. All six controls showed good expression of the SFRP5 protein. SFRP5 protein expression was not observed in any of the four cell lines (Figure 2b) . However, treatment of cell lines with DAC (5 mM for 72 h), a demethylation agent, resulted in SFRP5 protein expression. Results indicate that SFRP5 gene methylation may cause reduced SFRP5 protein expression in leukemia cells.
SFRP5 methylation upregulates mdr1 and P-gp Expression of mdr1 RNA was assessed. Expression of mdr1 mRNA was found in cells from three of the 12 patients with leukemia (L2, L7 and L8; Figure 3a ) who had shown SFRP5 gene methylation and reduced SFRP5 protein expression. In contrast, no control showed mdr1 mRNA expression. mdr1 mRNA expression was found in the KG1a cell line, but not in the other three cell lines ( Figure 3b) . P-gp protein expression was observed only in cells from the three patients (L2, L7 and L8) who expressed mdr1 mRNA (Figure 4a ). Similarly, P-gp expression was found only in the KG1a cell line (Figure 4b ). SFRP5 in leukemic cells multidrug resistance H Wang et al SFRP5 downregulation activates the Wnt/-catenin pathway As SFRP5 downregulation is thought to activate the Wnt/-catenin signaling pathway, 16 we investigated whether this pathway might be involved in mdr1 expression. As activation of the Wnt/-catenin pathway involves the dephosphorylation of -catenin, we examined the NP--catenin protein levels in cells from the five patients with reduced SFRP5 protein expression and in the four cell lines. The highest NP--catenin protein expression levels were found in cells from the three patients (L2, L7 and L8) who had also shown mdr1 mRNA expression (Figures 5a and b) , suggesting that a reduced expression of SFRP5 activates Wnt/-catenin and upregulates mdr1. The KG1a cell line showed substantially higher levels of NP--catenin expression compared with the other three cell lines (Figures 5c and d) .
Demethylation rescues SFRP5 protein expression Cells from patients L2, L7 and L8 and from the KG1a cell line were treated with DAC, resulting in the rescue of SFRP5 protein expression (Figure 6a ). This was associated with a decrease in P-gp expression (Figure 6b) . Furthermore, treatment with DAC significantly reduced mdr1 mRNA expression.
SFRP5 transfection rescues SFRP5 protein expression and downregulates mdr1
To better characterize the relevance of SFRP5 methylation in MDR, transgenic KG1a cells were generated. Transfection efficiency reached 90% (Figures 7a-d) . Consistently, flow cytometry experiments showed that eGFP-positive cells accounted for 92.1% of total cells. SFRP5 protein expression was detected in the KG1a/ SFRP5 cells, but not in KG1a/eGFP cells or untransfected KG1a cells (Figure 7e ). This confirms that our transfection technique was able to rescue SFRP5 expression in the KG1a cell line. SFRP5 rescue reduces P-gp expression Expression of mdr1 mRNA and P-gp protein was examined in KG1a/SFRP5 cells and showed downregulation of both mdr1 ( Figure 8a ) and P-gp (Figure 8b ), compared with KG1a/eGFP cells or untransfected KG1a cells. Reduced P-gp protein expression in KG1a/SFRP5 cells was also demonstrated (Figures 8c-e) , supporting a role for SFRP5 gene methylation and decreased SFRP5 protein expression in mdr1 and P-gp regulation.
SFRP5 transfection increases rhodamine accumulation
Rhodamine is a substrate of P-gp. 8 To establish whether changes in SFRP5 gene methylation and protein expression and in mdr1 and P-gp expression were related to the development of MDR, we measured intracellular levels of rhodamine. KG1a/SFRP5 cells were able to accumulate substantially higher levels of rhodamine than KG1a/eGFP cells or untransfected KG1a cells (Figure 9 ).
SFRP5 transfection decreases doxorubicin resistance
In order to compare the cytotoxic drug resistance of the three cell types, the MTT method was used to calculate the doxorubicin IC 50 values. The IC 50 values in KG1a, KG1a/eGFP and KG1a/SFRP5 cells were 0.963 ± 0.115, 0.917 ± 0.138 and 0.573 ± 0.131 mM. The lower IC 50 value observed for KG1a/SFRP5 cells is direct evidence that these cells were more sensitive to this agent, which was consistent with a lower MDR.
DISCUSSION
Our results showed that SFRP5 gene methylation and reduced SFRP5 protein expression may contribute to MDR development in leukemia through the canonical Wnt/-catenin pathway and enhanced expression of mdr1/P-gp. The highest levels of NP--catenin were observed in cells from three patients with leukemia with methylated SFRP5, and DAC rescued SFRP5 protein expression and inhibited mdr1/P-gp expression. Alterations in SFRP5 expression, secondary to SFRP5 gene methylation, may contribute to MDR in leukemia cells. Recovery of SFRP5 expression by gene transfection resulted in the downregulation of MDR.
Indeed, SFRP gene methylation and abnormal SFRP activity are associated with tumorigenesis in a variety of cancer types. [2] [3] [4] SFRP5 methylation was also associated with a worst prognosis in cervical and breast cancers. 5, 18, 19 SFRPs methylation was also reported in a variety of leukemia types and to be associated with prognosis. [12] [13] [14] [15] In the present study, SFRP5 was methylated in a number of leukemia patients and in all examined leukemia cells lines, whereas no control patient showed SFRP5 methylation. In addition, DAC was able to rescue SFRP5 expression in methylated SFRP5 cells. These results suggest that abnormal SFRP5 gene methylation may contribute to the development and/or progression of acute leukemia in some patients. In addition, SFRPs are thought to inhibit Wnt signaling. 16, 20 Abnormal Wnt activation was associated with colorectal cancers, head and neck cancers, melanoma, lung tumors and leukemia. [21] [22] [23] [24] [25] It is thus likely that the Wnt pathway mediates the tumorpromoting actions of SFRP gene methylation. Non-canonical Wnt proteins act through the Wnt/JNK and Wnt/Ca 2 þ pathways, [26] [27] [28] [29] whereas canonical Wnt proteins signal through -catenin, 9, 10, 30 resulting in activation of the T-cell factor/lymphocyte enhancer factor (TCF/LEF). 9 When the canonical Wnt signaling pathway is inactivated, phosphorylated -catenin is ubiquitinated and degraded. When Wnt signaling is activated, -catenin is dephosphorylated, allowing it to migrate to the nucleus, where it binds to TCF/LEF. The resulting DNA-binding complex promotes the transcription of various genes involved in cancers, including C-Myc, CCND1 and MMP-7. Wnt signaling is also involved in MDR, which includes mechanisms such as membrane transport proteins, 31 topoisomerases, 32 abnormal DNA damage and repair, and changes in the tumor microenvironment. 33 Several membrane transport proteins are involved in MDR, including P-gp, MDR proteins (MRPs) and breast cancer resistance protein (BCRP).
34-37 P-gp is recognized as a major factor in MDR. 8 Several commonly used chemotherapeutic drugs are substrates of P-gp. 8 In the present study, NP--catenin levels were increased in KG1a cells, suggesting an enhanced canonical Wnt/-catenin signaling, resulting in increased P-gp and MDR, shown by increased rhodamine efflux from the cells and by a better resistance to doxorubicin.
Different experimental approaches to suppress MDR were tested, [38] [39] [40] but these approaches are currently of limited value in a clinical setting. However, the present study suggests that the SFRP5/Wnt axis might be a target to decrease MDR in leukemia. Novel therapeutic strategies modulating this axis might improve leukemia patients' prognosis.
The present study is not without limitations. First, the small number of subjects precludes any firm conclusion on the methylation of SFRP5 in a population of leukemia patients. Nevertheless, SFRP5 methylation was only observed in leukemia patients and not in controls, suggesting a possible role of SFRP5 methylation in leukemia development and prognosis. However, Figure 4 . P-gp expression. P-gp expression was assessed in 12 leukemia patients (a) and in 4 cell lines (b) using western blotting. Expression of -actin was used as control. L1-L12, specimens from leukemia patients. . The effect of DAC on mdr1/P-gp expression in P-gppositive patient specimens and in the KG1a cell line. Western blotting was used to determine the effects of the demethylation agent, DAC, on SFRP5 protein levels (a) and P-gp (b). RT-PCR was used to examine the effects of DAC on RNA expression of mdr1 (c). Expression of -actin was used as control for the western blot experiments. *Po0.01 vs DAC( À ). L2, 7, 8, P-gp-positive specimens from leukemia patients; DAC, 5-aza-2-deoxycytidine.
SFRP5 in leukemic cells multidrug resistance H Wang et al SFRP5 was not methylated in all leukemia patients, suggesting that it is not obligatorily involved in leukemia development, but that it may be associated with a worst prognosis. Larger-scale epidemiological studies are needed to assess SFRP5 methylation in leukemia patients. Second, SFRP5 gene methylation was observed in seven leukemia patients and in the four cell lines, while Wnt/-catenin signaling appears to be upregulated in only three patients and one cell line, suggesting that other compensatory mechanisms may be present to inhibit Wnt/-catenin signaling. These mechanisms may involve other members of the SFRP family. Further studies are required to assess the interactions of these mechanisms in leukemia. Finally, doxorubicin is also a substrate of MRP1 and BCRP in addition to P-gp, 41 and we cannot exclude an influence of MRP1 and BCRP on our results. Future studies should be performed using paclitaxel, which is specific to P-gp, or by controlling for MRP1 and BCRP expression. Nevertheless, the aim of the present study was mainly to assess SFRP5 gene methylation on P-gp expression.
CONCLUSION
In conclusion, SFRP5 gene methylation in leukemia cells may act through the Wnt/-catenin pathway to upregulate mdr1/P-gp and cause MDR. Targeting SFRP5 gene methylation and expression may represent a novel therapeutic approach to inhibit MDR in leukemia cells. 
